Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - ropinirole - film-coated tablet - ropinirole 5 mg - anti-parkinson drugs

Malta - English - Medicines Authority

aspen pharma trading limited 3016 lake drive city west businees campus dublin 24, ireland - trimethoprim, sulfamethoxazole - solution for infusion - trimethoprim 80 mg/5ml sulfamethoxazole 400 mg/5ml - antibacterials for systemic use

Malta - English - Medicines Authority

aspen pharma trading limited 3016 lake drive city west businees campus dublin 24, ireland - trimethoprim, sulfamethoxazole - tablet - trimethoprim 80 mg sulfamethoxazole 400 mg - antibacterials for systemic use

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol - pressurised inhalation, suspension - salmeterol 25 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - ranitidine - solution for infusion or injection - ranitidine 25 mg/ml - drugs for acid related disorders

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - cefuroxime - film-coated tablet - cefuroxime 500 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - cefuroxime - granules for oral suspension - cefuroxime 125 milligram(s)/5 millilitre - antibacterials for systemic use

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - aciclovir - oral suspension - aciclovir 200 mg/5ml - antivirals for systemic use

United States - English - NLM (National Library of Medicine)

rebel distributors corp - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 500 mg - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. keppra is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in keppra tablets or oral solution. safety and effectiveness in patients below 4 years of age have not been established. studies of levetiracetam in juvenile rats (dosing from day 4 through day 52 of age) and dogs (dosing from week 3 through week 7 of age) at doses of up to 1800 mg/kg/day (approximately 7 and 24 times, respectively, the maximum recommended pediatric

United States - English - NLM (National Library of Medicine)

rebel distributors corp - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 500 mg - levetiracetam tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in levetiracetam tablets. the abuse and dependence potential of levetiracetam has not been evaluated in human studies.